Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]
Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]